Who
Mark Germain
Director
Company insider
Files Form 4 as: Director, Scinai Immunotherapeutics; Director, Pluri; Director, Niagen Bioscience; Director, Reis.
In numbers
- Trades disclosed
- 82
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $511K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 20 Jun 2007
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | SCNI Scinai ImmunotherapeuticsBiotechnology | SEC FORM 4 Code A | —120,000,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | SCNI Scinai ImmunotherapeuticsBiotechnology | SEC FORM 4 Code A | —120,000,000 at $0.00 | filing |
| 10 Sep 2020filed 10 Sep 2020 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 Dec 2018filed 20 Dec 2018 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —62,625 at $0.00 | filing |
| 19 Dec 2018filed 20 Dec 2018 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —49,125 at $0.00 | filing |
| 16 Mar 2018filed 19 Mar 2018 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $17K11,640 at $1.48 | filing |
| 15 Mar 2018filed 19 Mar 2018 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $51K34,233 at $1.48 | filing |
| 14 Mar 2018filed 15 Mar 2018 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $36K23,818 at $1.50 | filing |
| 14 Dec 2017filed 14 Dec 2017 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 29 Dec 2016filed 29 Dec 2016 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —65,500 at $0.00 | filing |
| 5 Jan 2016filed 7 Jan 2016 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 8 Jan 2015filed 8 Jan 2015 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 18 Jun 2014filed 27 Jun 2014 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 18 Jun 2014filed 19 Jun 2014 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $70K22,500 at $3.10 | filing |
| 18 Jun 2014filed 19 Jun 2014 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $34K10,715 at $3.13 | filing |
| 18 Jun 2014filed 19 Jun 2014 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $16K5,000 at $3.13 | filing |
| 18 Jun 2014filed 19 Jun 2014 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $16K5,000 at $3.15 | filing |
| 4 Mar 2014filed 5 Mar 2014 | PLUR PluriBiotechnology | SEC FORM 4 Sold | $273K67,858 at $4.02 | filing |
| 21 Jan 2014filed 23 Jan 2014 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 26 Dec 2013filed 26 Dec 2013 | PLUR PluriBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
News
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the CompanyPLUR · manilatimes.net · 21 Oct 2026Head to Head Comparison: Cytokinetics (NASDAQ:CYTK) vs. Pluri (NASDAQ:PLUR)PLUR · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Mark Germain; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.